Lecanemab

Introduction Overview

Generic Name

lecanemab

Brand Name

Leqembi

Dosage Form

injection for infusion

Drug Class

Miscellaneous central nervous system agents

Pharmacokinetics

Absorption:
Lecanemab is administered intravenously via infusion, thus bypassing the gastrointestinal tract and obviating absorption variability seen in oral administration. The intravenous route ensures complete bioavailability, with direct delivery into systemic circulation. Consequently, absorption-related factors such as gastric pH, motility, and interactions with food or other drugs are not applicable to lecanemab.

Distribution:
Following intravenous infusion, lecanemab, a monoclonal antibody of approximately 150 kDa, distributes primarily within the vascular and interstitial spaces. Due to its large molecular size and hydrophilic nature, lecanemab has limited penetration across the blood-brain barrier; however, a small fraction can cross into the central nervous system (CNS) to reach amyloid plaques. The extent of CNS penetration is influenced by the integrity of the blood-brain barrier and inflammation. Volume of distribution approximates plasma and extracellular fluid volume. Lecanemab likely engages amyloid-beta plaques in the brain parenchyma through this CNS fraction.

Metabolism:
As a monoclonal antibody, lecanemab undergoes catabolism via ubiquitous proteolytic pathways, primarily through the reticuloendothelial system and lysosomal degradation within cells. It is metabolized into small peptides and amino acids that are recycled or excreted. No hepatic cytochrome P450 metabolism is involved, minimizing the risk of hepatic drug-drug interactions. The specific pathways of clearance involve Fc receptor-mediated endocytosis and degradation within phagocytic cells.

Elimination:
Lecanemab elimination occurs predominantly through catabolic degradation rather than renal or hepatic excretion of intact drug. The estimated terminal half-life of lecanemab is consistent with other IgG1 antibodies, approximately 7 to 14 days, supporting the dosing interval of biweekly infusions initially. Clearance may be influenced by factors such as anti-drug antibody formation or patient immunocompetence but generally remains consistent. There is no significant renal or hepatic clearance measured, and dosing adjustments based on organ impairment are not established.

Dosage Forms

Available Dosage Forms:
Leqembi is commercially available as the following single-dose vials containing lecanemab-irmb:
- 200 mg per 2 mL (concentration of 100 mg/mL)
- 500 mg per 5 mL (concentration of 100 mg/mL)
These vials are for intravenous infusion and require dilution as per prescribing information.

Dosages for Adults and Adolescents:
The recommended dosing regimen for adults with mild cognitive impairment or mild dementia due to Alzheimer's disease is 10 mg/kg based on actual body weight. The injection is diluted and administered as an intravenous infusion over approximately one hour every two weeks for the first 18 months of therapy. Following this initial treatment period, dosing intervals may be extended to once every four weeks based on clinical judgment and patient response.

Specific Patient Populations:
Pediatric use of lecanemab is not established, as Alzheimer's disease primarily affects the elderly. There is no current evidence prescribing adjustments for renal or hepatic impairment, as monoclonal antibodies are metabolized proteolytically rather than eliminated renally or hepatically. Elderly patients aged typical for Alzheimer's disease were included in clinical trials without dose adjustment. Caution is advised in patients with a history of immunologic reactions or risk factors for amyloid-related imaging abnormalities (ARIA). Pregnant and breastfeeding patients should consult healthcare providers, as safety has not been fully established in these populations.

Mechanism Of Action

Leqembi (lecanemab) is a humanized monoclonal antibody that selectively targets amyloid beta (Aβ) species implicated in the pathogenesis of Alzheimer's disease. Its primary molecular mechanism involves high-affinity binding to aggregated soluble Aβ protofibrils and insoluble fibrils present in cerebral amyloid plaques. By binding these Aβ species, lecanemab facilitates their clearance via microglial-mediated phagocytosis and possibly peripheral sink mechanisms.

At the cellular level, lecanemab interacts with amyloid plaques and protofibril aggregates, stabilizing them and promoting immune system recognition through Fc receptor engagement on microglia. This immune activation leads to enhanced phagocytic removal of amyloid deposits in the brain, reducing neurotoxic amyloid burden. The reduction of amyloid plaque density mitigates synaptic dysfunction and neuronal death that contribute to cognitive decline.

Biochemically, lecanemab exhibits specificity for Aβ1-42 protofibrils, the toxic soluble aggregates responsible for synaptic impairment. Unlike other antibodies that may preferentially target monomeric or plaque-bound amyloid, lecanemab has a unique affinity for protofibrils, which are intermediates in plaque formation, making it effective both in preventing new plaque aggregation and clearing existing plaques.

Clinically, this mechanism translates into slowed progression of cognitive and functional decline in early Alzheimer's disease patients, as demonstrated by reductions in biomarkers of amyloid pathology and improved clinical outcomes in trials. Comparative studies with other anti-amyloid agents suggest lecanemab’s balanced targeting of protofibrils and plaques may provide a favorable efficacy and safety profile. Continued research is elucidating the precise kinetic interactions and potential long-term benefits of lecanemab’s mechanism of action in neurodegeneration.

Pharmacological Actions

Selective binding to aggregated soluble and insoluble amyloid beta protofibrils and fibrils in the brain.
Facilitation of microglial-mediated phagocytosis and clearance of amyloid beta plaques.
Reduction of amyloid beta plaque burden leading to decreased neuronal toxicity.
Modulation of neuroinflammatory pathways via Fc receptor engagement on microglial cells.
Slowing cognitive decline in patients with mild cognitive impairment or early Alzheimer's dementia.
Potential interference with amyloid beta aggregation and plaque formation process.
Intravenous monoclonal antibody activity providing systemic and central nervous system availability.
Reduction of synaptic dysfunction by lowering neurotoxic amyloid species.
Minimal cytochrome P450 involvement reducing metabolic drug-drug interactions.
Immunomodulatory activity eliciting both clearance and potential immune-related adverse effects.
Improvement in functional and memory outcomes in clinical trials.
Ability to cross blood-brain barrier sufficiently to exert central therapeutic effects.
Distinct protofibril targeting differentiating it from other anti-amyloid therapeutics.

Therapeutic Or Clinical Uses

Treatment of Alzheimer's disease in patients with mild cognitive impairment (MCI).
Management of mild dementia due to Alzheimer's disease.
Slowing cognitive decline measured by global cognitive scales such as CDR-SB.
Reduction of amyloid beta plaque burden in the brain.
Adjunctive therapeutic option for early Alzheimer's disease to delay symptom progression.
Used in patients with confirmed amyloid beta pathology via diagnostic imaging.
Potential to improve memory, thinking, and behavior in mild Alzheimer's disease.
Therapeutic intervention aiming to modify underlying pathological processes rather than symptomatic treatment.
Alternative or complementary treatment in patients not adequately managed with cholinesterase inhibitors or memantine.
Treatment for patients with genetic risk factors when monitored carefully for side effects.
Enabled by intravenous administration in specialized healthcare settings.
Potential use within a comprehensive Alzheimer’s management plan including cognitive rehabilitation.
Option for patients with biomarker-confirmed early-stage Alzheimer's disease.
May delay progression to moderate or severe dementia.
Useful in clinical trials and settings evaluating anti-amyloid therapies.

Side Or Adverse Effects

Infusion-related reactions occurring in approximately 26% of patients, including fever, chills, nausea, vomiting, hypotension, hypertension, and oxygen desaturation.
Headache, reported as a common side effect in clinical trials.
Amyloid-related imaging abnormalities (ARIA), including brain swelling (ARIA-E) and microhemorrhages or superficial siderosis (ARIA-H).
Potential for severe ARIA symptoms such as confusion, dizziness, vision changes, nausea, difficulty walking, and seizures.
Serious allergic reactions including facial, lip, mouth, or tongue swelling, hives, and breathing difficulties.
Mild to moderate infusion reactions leading occasionally to treatment discontinuation.
Local infusion site reactions including redness or irritation.
Flu-like symptoms such as generalized aches and joint pain during or shortly after infusion.
Rare but serious hemorrhagic events in the brain, especially in patients with risk factors.
Potential transient worsening of cognitive or neurological symptoms related to ARIA.
Fatigue and malaise reported post-infusion in some patients.
Nervous system effects related to brain imaging abnormalities necessitating close monitoring.
Gastrointestinal disturbances like nausea linked to infusion reactions.
Hypersensitivity or immunologic reactions requiring prompt medical intervention.
Potential increased risk of bleeding, especially when used concomitantly with antithrombotic agents.

Precautions

Use cautiously in patients with known bleeding disorders or those on anticoagulation therapies due to increased risk of brain hemorrhage.
Screening and monitoring with periodic MRI scans are essential to detect ARIA before symptomatic presentation.
Test for apolipoprotein E (ApoE) genotype to assess risk for developing ARIA, particularly homozygous carriers who have increased susceptibility.
Pre-infusion prophylaxis with antihistamines, acetaminophen, NSAIDs, or corticosteroids may be considered to minimize infusion reactions.
Discontinue or delay infusion upon clinical signs of serious infusion-related reactions or severe ARIA symptoms.
Monitor for signs of allergic or anaphylactic reactions during and after infusion, with readiness for emergency intervention.
Consider risk-benefit balance in older adults or those with advanced Alzheimer's disease as clinical trials focused on early disease stages.
Evaluate pregnancy status; use only if potential benefit justifies potential risk, as safety in pregnancy is not established.
Consult healthcare providers before breastfeeding due to unknown excretion into milk and potential effects on infant.
Avoid abrupt discontinuation without medical advice; dosing intervals may be adjusted by healthcare provider based on clinical response.
Assess concomitant medications for possible interactions increasing bleeding risk or immunosuppression.
Educate patients and caregivers on recognizing urgent symptoms like sudden severe headache or neurological deficits.
Ensure infusion is administered by trained healthcare professionals in a setting equipped to manage adverse reactions.
Maintain patient hydration and stable vital signs before initiation of infusion.
Report any adverse events to healthcare providers promptly to optimize safety monitoring.

Warnings

Boxed warning for amyloid-related imaging abnormalities (ARIA) including brain edema (ARIA-E) and hemorrhagic events (ARIA-H).
Risk of serious symptoms from ARIA such as headache, confusion, dizziness, vision changes, seizures, and gait disturbance.
Possible life-threatening allergic reactions including anaphylaxis require immediate medical intervention.
Infusion-related reactions that may necessitate infusion rate modification or discontinuation.
Elevated risk of ARIA in patients homozygous for apolipoprotein E ε4 allele necessitating genetic risk assessment.
Concomitant use with antithrombotic or anticoagulant medications can elevate risk for intracerebral hemorrhage.
Not a cure for Alzheimer's disease; therapeutic benefits are modest and must be weighed against potential risks.
MRI monitoring before treatment initiation and periodically thereafter is mandatory to detect asymptomatic or symptomatic ARIA.
Patients should be educated to report any neurological symptoms immediately for prompt evaluation.
Safety and efficacy in patients with moderate to severe Alzheimer's disease have not been established.
Use caution in patients with prior history of brain hemorrhage or vascular malformations.
Limited data in pregnant or breastfeeding women; potential fetal risk cannot be excluded.
Potential for immune-mediated adverse effects due to monoclonal antibody administration.
Ensure proper storage and handling to maintain drug integrity and efficacy.
Healthcare providers should have protocols in place to manage infusion reactions and severe hypersensitivity.

Contraindication

Known hypersensitivity or allergic reaction to lecanemab or any component of the formulation.
Patients with ongoing brain hemorrhage or significant cerebral vascular disease contraindicated due to bleeding risk.
History of severe infusion-related or anaphylactic reaction to anti-amyloid monoclonal antibodies.
Use contraindicated in moderate to severe Alzheimer's disease where safety and efficacy have not been demonstrated.
Contraindicated in patients with uncontrolled systemic illnesses that may increase risk of serious adverse events.
Do not administer to patients with active infection at the infusion site or systemic infections.
Contraindications exist if patient cannot comply with MRI monitoring or clinical follow-up.
Known or suspected pregnancy without clear benefit-risk assessment is contraindicated.
Contraindicated in patients with coagulopathies where bleeding risk outweighs therapeutic benefits.
Patients with severe renal or hepatic impairment have not been studied; use with caution.
Contraindicated if any component of the formulation including excipients produce hypersensitivity.
Patients with history of severe autoimmune or immune deficiency disorders may be excluded due to immune-mediated risks.
Children and adolescents due to lack of established safety and efficacy.
Concomitant use with drugs known to drastically increase risk of cerebral hemorrhage may be contraindicated.
Contraindicated if inability to undergo safety monitoring including MRI.

Drug Interactions

Concomitant administration with antithrombotic or anticoagulant medications (e.g., aspirin, warfarin, direct oral anticoagulants) increases risk of intracerebral hemorrhage and bleeding complications.
Potential interaction with other monoclonal antibodies or immunomodulatory agents that may alter immune response or increase infusion reaction risk.
No known cytochrome P450 metabolic interactions as lecanemab is catabolized proteolytically; minimizes classical drug metabolism interactions.
Possible increased risk of infusion reactions with co-administration of other biologics or immune-targeting therapies.
Concomitant use of corticosteroids, NSAIDs, or antihistamines may be employed as premedications to reduce infusion reactions; no negative pharmacokinetic interactions reported.
No clinically significant interactions reported with common Alzheimer's disease supportive medications such as donepezil or memantine.
Medications that affect blood pressure may complicate management of infusion-related hypotension or hypertension.
Drugs influencing immune status (e.g., immunosuppressants) may alter efficacy or safety profile of lecanemab.
No specific interaction with herbal supplements or vitamins documented, but clinicians should evaluate all concomitant products individually.
Polypharmacy in elderly patients increases monitoring needs due to potential cumulative adverse effects.
Drug interactions that increase risk of seizures could be of particular concern due to ARIA-associated neurological symptoms.
Medications causing hypoxia or affecting oxygen saturation could exacerbate infusion-related adverse effects.
No significant pharmacodynamic antagonism or synergy with other FDA-approved Alzheimer's therapies identified.
No established interaction with agents altering blood-brain barrier permeability, though theoretical considerations exist.
Healthcare providers should maintain vigilance for unexpected adverse interactions during post-marketing surveillance.

Preparations Of The Drug

Leqembi is supplied as a sterile, preservative-free solution for intravenous infusion in single-dose vials.
Available vial strengths are 200 mg/2 mL and 500 mg/5 mL, each with a concentration of 100 mg/mL.
The solution contains active ingredient lecanemab-irmb and inactive ingredients including arginine hydrochloride, histidine, histidine hydrochloride monohydrate, polysorbate 80, and water for injection.
Vials are packaged in cartons and should be stored refrigerated at 2°C to 8°C (36°F to 46°F) in the original carton to protect from light.
The drug must not be frozen or shaken to maintain stability and efficacy.
Prior to administration, the drug is diluted according to prescribing information and should be used immediately or stored refrigerated for up to 4 hours or at room temperature (up to 30°C) for no more than 4 hours post-dilution.
The infusion preparation requires aseptic technique by qualified healthcare professionals in a controlled clinical environment.
The medication dose is calculated based on patient body weight (10 mg/kg) and delivered via intravenous infusion over approximately one hour.
Premedication with antihistamines, acetaminophen, NSAIDs, or corticosteroids may be used to minimize infusion reactions.
The formulation is compatible with standard infusion equipment and diluents as per package insert instructions.
Discard any unused portion as the product is preservative free and intended for single use to prevent contamination.
Efforts must be taken to avoid exposure to light and extremes of temperature during storage and handling.
Patient counseling on the preparation, administration, and potential adverse effects should accompany drug delivery.
The manufacturer Eisai Inc. provides additional patient support and medication assistance programs.